WallStreetZenWallStreetZen

NASDAQ: XERS
Xeris Biopharma Holdings Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

XERS past revenue growth

How has XERS's revenue growth performed historically?
Company
48.68%
Industry
145.73%
Market
17.2%
XERS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
XERS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
XERS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

XERS earnings and revenue history

Current Revenue
$163.9M
Current Earnings
-$62.3M
Current Profit Margin
-38%

XERS Return on Equity

Current Company
-610.8%
Current Industry
-63.5%
Current Market
188%
XERS's Return on Equity (-610.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when XERS announces earnings.

XERS Return on Assets

Current Company
-19.1%
Current Industry
2.9%
XERS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

XERS Return on Capital Employed

Current Company
-16.22%
Current Industry
19.5%
XERS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

XERS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
XERS$163.91M-$23.74M-$62.26M+132.30%N/A
VTYX$0.00-$192.02M-$192.96MN/AN/A
INO$832.01k-$130.39M-$135.12M-51.33%N/A
PBYI$235.64M$47.52M$21.59M-1.25%N/A
NKTR$90.12M-$243.11M-$276.06M-40.35%N/A
View Top Biotech Stocks

XERS earnings dates

Next earnings date
Jun 5, 2024

Xeris Biopharma Holdings Earnings & Revenue FAQ

What were XERS's earnings last quarter?

On Invalid Date, Xeris Biopharma Holdings (NASDAQ: XERS) reported Q4 2023 earnings per share (EPS) of -$0.09, up 10% year over year. Total Xeris Biopharma Holdings earnings for the quarter were -$13.39 million. In the same quarter last year, Xeris Biopharma Holdings's earnings per share (EPS) was -$0.10.

If you're new to stock investing, here's how to buy Xeris Biopharma Holdings stock.

What was XERS's earnings growth in the past year?

As of Q2 2024, Xeris Biopharma Holdings's earnings has grown year over year. Xeris Biopharma Holdings's earnings in the past year totalled -$62.26 million.

What is XERS's earnings date?

Xeris Biopharma Holdings's earnings date is Invalid Date. Add XERS to your watchlist to be reminded of XERS's next earnings announcement.

What was XERS's revenue last quarter?

On Invalid Date, Xeris Biopharma Holdings (NASDAQ: XERS) reported Q4 2023 revenue of $44.39 million up 33.93% year over year. In the same quarter last year, Xeris Biopharma Holdings's revenue was $33.14 million.

What was XERS's revenue growth in the past year?

As of Q2 2024, Xeris Biopharma Holdings's revenue has grown 48.68% year over year. This is 97.05 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Xeris Biopharma Holdings's revenue in the past year totalled $163.91 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.